Ex­clu­sive: Myeloid Ther­a­peu­tics moves sec­ond in vi­vo cell ther­a­py in­to tri­als, tar­get­ing liv­er can­cer

Myeloid Ther­a­peu­tics brought a sec­ond in vi­vo cell ther­a­py pro­gram in­to the clin­ic, once again tak­ing aim at hard-to-treat sol­id tu­mors, the Cam­bridge, MA-based biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER